ClinicalTrials.gg
TerminatedNCT05999968Updated Jun 26, 2026

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

A Phase 1 interventional study of Abemaciclib and Darolutamide in Prostatic Neoplasms, sponsored by Eli Lilly and Company. Terminated at 13 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.

Enrollment
6th of 10
10 · median 15
Started
2024
the only one that year
Phase 1
2 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
4 of 10
Eli Lilly and Company

Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 1, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing abemaciclib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate.
  • castration-resistant prostate cancer evidenced by:

    • Prostate-specific antigen (PSA) or radiographic progression despite castrate levels of testosterone
    • At least 1 bone metastasis on bone scan and/or 1 soft tissue metastasis on computed tomography/magnetic resonance imaging (CT/MRI)
  • Participants who have not undergone bilateral orchiectomy must continue luteinizing-hormone-releasing hormone (LHRH) agonists/antagonists throughout the study.
  • Have adequate organ function.
  • (ECOG) performance status (PS) 0-1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors or darolutamide.
  • Prior systemic therapy for castration-resistant prostate cancer(mCRPC) with cytotoxic chemotherapy, PARP inhibitors, novel hormonal agents (NHAs) (enzalutamide, apalutamide, and abiraterone), and radiopharmaceuticals.
  • Serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
  • heart disease as evidenced by myocardial infarction, arterial thrombotic events, severe or unstable angina, or congestive heart failure ( Class III or IV) within 6 months of assignment to treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Darolutamide

    Abemaciclib plus (+) darolutamide. Participants who have not undergone bilateral orchiectomy are required to continue background androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist/antagonist throughout the study.

    Drug: Abemaciclib · Drug: Darolutamide · Drug: LHRH agonist/antagonist

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Administration Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Date of first dose to study completion (approximately 32 months)

Secondary outcomes

  1. Radiographic Progression-Free Survival (rPFS) Assessed by Investigator rPFS Assessed by Investigator

    rPFS Assessed by Investigator

    Time frame: Date of first dose to radiographic disease progression or death from any cause (approximately 32 months)

  2. Objective Response Rate (ORR): Percentage of Participants with Soft Tissue Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)

    ORR: Percentage of Participants with Soft Tissue BOR of CR or PR

    Time frame: Date of first dose to radiographic disease progression or death from any cause (approximately 32 months)

  3. Duration of Response (DoR)

    DOR

    Time frame: Date of first documented CR or PR to radiographic disease progression or death from any cause (approximately 32 months)

  4. Time to Prostate Specific Antigen (PSA) Progression

    Time to PSA progression

    Time frame: Date of first dose to the first observation of PSA progression (approximately 32 months)

  5. Prostate Specific Antigen (PSA) Response Rate (PSA-RR): Percentage of Participants with a PSA Decrease of at Least 50% from Baseline

    PSA-RR

    Time frame: Date of first dose to confirmed PSA progression (approximately 32 months)

  6. Pharmacokinetics (PK): Mean Concentrations of Abemaciclib and its Active Metabolite(s)

    PK: Mean Concentrations of Abemaciclib and its Active Metabolite(s)

    Time frame: Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle = 28 days)

  7. Pharmacokinetics (PK): Mean Concentrations of Darolutamide and its Active Metabolite

    PK: Mean Concentrations of Darolutamide and its Active Metabolite

    Time frame: Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle = 28 days)

07

Study locations

13 sites
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Studienpraxis Urologie
    Nürtingen, Baden-Wurttemberg 72622, Germany
  • Klinikum Rechts Der Isar Der Technischen Universität München
    Munich, Bavaria 81675, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Instituto Catalan de Oncologia - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Catalunya [Cataluña] 8907, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Madrid, Comunidad de 28009, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad de 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
  • Hospital Infanta Cristina
    Badajoz, 06006, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Feb 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Jan 12, 2024
Primary completionActual
Feb 23, 2024
CompletionActual
Jan 21, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999968
Collaborators
Bayer
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 12, 2024
Primary completion
Feb 23, 2024
Completion
Jan 21, 2026
Last update
Jun 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Darolutamide

Start the discussion